Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Neuroblastoma 6Glioblastoma 6Melanoma 5Neoplasms 3Leukemia, Myeloid, Acute 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pathologic Complete Response 2Ovarian Neoplasms 2Osteosarcoma 2Lung Neoplasms 2Liver Neoplasms 2Gliosarcoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Wilms Tumor 1Vaccinia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1

Interventions

Pemetrexed 13Cisplatin 12Nivolumab 5Carboplatin 5pembrolizumab 4Ipilimumab 4Cyclophosphamide 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3fludarabine 3defactinib 3amatuximab 2Paclitaxel 2Gemcitabine 2Drug Therapy 2tremelimumab 1tazemetostat 1osimertinib 1napabucasin 1enzalutamide 1bemcentinib 1abemaciclib 1VS-5584 1Trabectedin 1Thiostrepton 1Safety 1Panobinostat 1Monatide (IMS 3015) 1Midazolam 1Letrozole 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma, Malignant × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT01265433 2024-10-09

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Sellas Life Sciences Group

Phase 2 Completed
41 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡